Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » Business, Policy & Funding » Research Funding » FDA Awards $2.4M to Vanderbilt Researcher for Duchenne Muscular Dystrophy Biomarker Study

FDA Awards $2.4M to Vanderbilt Researcher for Duchenne Muscular Dystrophy Biomarker Study

Oct 08, 2019
|
staff reporter

NEW YORK — The US Food and Drug Administration has awarded researchers from Vanderbilt University a roughly $2.4 million grant to identify genetic and other biomarkers that can be used to determine the severity and progression of cardiac dysfunction associated with Duchenne muscular dystrophy (DMD).

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Scan

Suit and Settlement

Los Angeles brought and settled a civil enforcement action against the makers of an at-home test for SARS-CoV-2, NPR reports. 

CRUK Announces Cuts

The Guardian reports that Cancer Research UK is cutting its research funding by £44 million.

Long Wait

Technology Review examines factors affecting SARS-CoV-2 testing turnaround times.

PNAS Papers on Ancient European Migrations, Triple-Negative Breast Cancer Fusions, More

In PNAS this week: mapping of ancient human migrations in Europe, recurrent gene fusion in breast cancer, and more.

May
06
Featured Webinar

The Role of Single-Cell Functional Biomarkers in Next-Generation Cancer Therapies

Sponsored by
Isoplexis

This webinar will discuss the application of single-cell proteomics and immune-imaging in adoptive cell therapy (ACT) for cancer.

What's Popular?

In Biomarker Discovery & Validation

  1. Blood-Based Genetic Risk Score Shows Promise for Prostate Cancer Drug Response, Survival Prediction

    Premium

  2. Gilead Sciences, Second Genome Partner for Microbiome-Based IBD Biomarker, Drug Discovery

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.